Supplementary Figure S7 from <i>NPY</i> Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer

類似資料

• Supplementary Figure S1 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
  著者:: Javier Pascual (15018176)
  出版事項: (2025)
• Supplementary Figure S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
  著者:: Javier Pascual (15018176)
  出版事項: (2025)
• Supplementary Figure S3 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
  著者:: Javier Pascual (15018176)
  出版事項: (2025)
• Supplementary Figure S4 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
  著者:: Javier Pascual (15018176)
  出版事項: (2025)
• Supplementary Figure S5 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
  著者:: Javier Pascual (15018176)
  出版事項: (2025)